Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States

Published:2018-10-16 Issue:12 Volume:21 Page:1238-1245
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Roth Joshua A.¹²,Sullivan Sean D.¹²,Lin Vincent W.³,Bansal Aasthaa¹²,Purdum Anna G.³,Navale Lynn³,Cheng Paul³,Ramsey Scott D.¹²

Affiliation:

1. Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Institute, Seattle, WA, USA;

2. Comparative Health Outcomes, Policy and Economics Institute, School of Pharmacy, University of Washington, Seattle, WA, USA;

3. Kite, a Gilead Company, Santa Monica, CA, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1529674

Reference38 articles.

1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

2. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

3. Accounting for Cured Patients in Cost-Effectiveness Analysis

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review;Value in Health;2024-08

2. The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain;Cancers;2024-07-30

3. Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain;Cancers;2024-06-22

4. Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial;Future Oncology;2024-06-05

5. A Review of the Cost-Effectiveness Evidence for FDA-Approved Cell and Gene Therapies;Human Gene Therapy;2024-06-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3